Minehead community pool campaign launched by two groups
Two community groups are working to try and secure funding for a new public swimming pool in Minehead.The town, home to the Butlins leisure resort, has not had a public pool since the closure of the Aquasplash facility in 2008 on the grounds it was not cost effective. Minehead Health and Well-Being (MH&WB) and Minehead Swimming and Leisure (MSL) say they want to develop land off Irham Road to be run as a cooperative. Both groups say they will raise funding, but no formal bids have been made yet.
Somerset Council said: "Minehead Health and Well-Being has made contact with our officers to discuss the project, and has outlined its intention to continue to develop the concept with the support of Minehead Town Council".Bruce Lang, a director of Minehead Health and Well-Being, said: "Our directors have considerable experience in project development, local government, finance, public health, fundraising, leisure, swimming development and education."MSL has wide experience in community consultation and structures. We make an ideal partnership."There is a lot of work to do, but by working together and combining our local knowledge and expertise, we hope to deliver a project that will benefit all of the local Minehead and west Somerset community."Peter Wellstood, founding director of Minehead Swimming & Leisure, said: "We have a lot in common when it comes to our ambitions for the local community, and we view our coming together as a real boost towards finally making the facility a reality.According to the Local Democracy Reporting Service, the groups' joint vision entails the construction of a 25-metre pool suitable for year-round use, along with a fully-equipped gym.The pool would also be used as a base for the West Somerset GP exercise referral scheme.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
34 minutes ago
- Daily Mail
Mounjaro has cured me of these three common life-limiting conditions. I'm healthier now at 60 than I was at 40...
Since mid-January, I've been hiding a secret drug habit. Once a week I sneak off and jab myself with a syringe I bought online. Aged 60, I am one of the fast-growing band of midlife women using 'skinny jabs' even though I'm not obese (I'm 5ft 7in tall, back then weighed 13st and I don't have diabetes.)
Daily Mail
34 minutes ago
- Daily Mail
The expert's guide to what microplastics do to your body - and 22 ways to minimise your risk
When Orlando Bloom, 48, was pictured having a £10,000, two-hour treatment to remove microplastics from his blood, it thrust the subject back into the spotlight. 'Microplastics are the tiny plastic particles that you often can't see, as they're less than five millimetres, but they're everywhere,' explains Dr Liza Osagie-Clouard, a former surgeon and now founder of Solice, a preventative healthcare clinic.
Sky News
35 minutes ago
- Sky News
New leukaemia treatment hailed as 'milestone' in cancer management
A combination of targeted drugs, offering a chemotherapy-free approach to leukaemia, have been hailed a "milestone" in cancer care by scientists following a groundbreaking UK trial. Potentially offering better outcomes for some patients as well as being more tolerable, it could reshape the way chronic lymphocytic leukaemia (CLL) - the most common form of leukaemia in adults - is treated. The Flair trial took place at 96 cancer centres across the UK. Researchers from Leeds wanted to assess whether two targeted cancer drugs could perform better than standard chemotherapy among patients with CLL. Some 786 people with previously untreated CLL were randomly assigned to receive standard chemotherapy; a single targeted drug, ibrutinib, or two targeted drugs taken together, ibrutinib and venetoclax, with treatment guided by personalised blood tests. Ibrutinib is a type of drug known as a cancer growth blocker. It works by stopping signals that cancer cells use to divide and grow. Venetoclax blocks the functions of a protein found in CLL cells. Researchers found that after five years, 94% of patients who received ibrutinib plus venetoclax were alive with no disease progression. That compared with 79% for those on ibrutinib alone and 58% for those on standard chemotherapy, according to the study, which has been published in the New England Journal of Medicine and presented to the European Haematology Association congress in Milan, Italy. Meanwhile 66% of patients on the new combination had no detectable cancer in their bone marrow after two years, compared with none of the people who received ibrutinib alone and 48% on chemotherapy. Experts said that the new treatment regime was also tolerated better than traditional treatments. 'An era of truly personalised medicine' Dr Talha Munir, consultant haematologist at Leeds Teaching Hospitals NHS Trust, who led the study said: "Flair trial is a milestone. "We have shown that a chemotherapy-free approach can be not only more effective but also more tolerable for patients. "By tailoring individualised treatment based on how well the cancer responds, we're moving into an era of truly personalised medicine." Catherine Whitfield, 63, from Farnley, West Yorkshire, was diagnosed with CLL in 2018 after she noticed symptoms including bleeding gums, constant illness and neck pain. She signed up to the trial, which was coordinated by the Leeds Cancer Research UK Clinical Trials Unit at the University of Leeds and sponsored by the University of Leeds. She said: "After three years of treatment, I am still MRD negative - that means no cancer cells. "I lost my husband to cancer. I have seen how hard it could be. "My first thought after my diagnosis was, I will never see my grandchildren being born and growing up. "Now I have two grandchildren, Drew and Alaia, and they are a delight and highlight the joys of a healthy life." 'Kinder, more targeted treatment' Ms Whitfield added: "The way this trial was explained, it just made sense. "Also, the thought of chemotherapy was scary to me. The trial felt right. And it was." Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, which funded the trial along with AbbVie, and Johnson and Johnson, said: "The results of the Flair trial show that we can provide kinder, more targeted treatment for chronic lymphocytic leukaemia, which gives people with CLL more precious time with their loved ones. "We're hopeful that the results of the Flair trial will power new treatment options for leukaemia and other blood cancers, thanks to the efforts of researchers in Leeds and across the UK working together on this trial." CLL is the most common form of leukaemia in adults, affecting the blood and bone marrow. While it cannot usually be cured, it can be managed with treatment.
